Effect of Erythropoietin on Bone Marrow Uptake of 18F-Fluorocholine in Prostate Cancer Comparison With 18F-Fluoride Uptake

被引：9
作者：
Balogova, Sona [1 ,2 ]
Huchet, Virginie [1 ]
Egrot, Christoph [1 ,3 ]
Michaud, Laure [1 ]
Paycha, F. [1 ]
Kerrou, Khaldoun [1 ]
Montravers, Francoise [1 ]
Cussenot, Olivier [1 ,3 ]
Talbot, Jean Noel [1 ]
机构：
[1] Univ Paris 06, Hop Tenon, AP HP, Dept Nucl Med, Paris, France
[2] Comenius Univ, Bratislava, Slovakia
[3] Univ Paris 06, Hop Tenon, AP HP, Dept Urol, Paris, France
来源：
CLINICAL NUCLEAR MEDICINE | 2013年 / 38卷 / 03期
关键词：
prostate cancer; F-18-fluorocholine; F-18-fluoride; erythropoietin; bone marrow activation; POSITRON-EMISSION-TOMOGRAPHY; PET/CT; FLUOROCHOLINE; F-18; METASTASES; EXPERIENCE; PATIENT; RELAPSE;
D O I：
10.1097/RLU.0b013e31827a2294
中图分类号：
R8 [特种医学]; R445 [影像诊断学];
学科分类号：
1002 ; 100207 ; 1009 ;
摘要：
The effect of erythropoietin stimulation on bone marrow uptake of FDG has been well documented. Similar metabolic activation of bone marrow with F-18-fluorocholine (FCH) has not been previously reported. FCH PET/CT was performed in a patient with biochemical recurrent prostate cancer who was receiving erythropoietin for hemochromatosis. Diffuse skeletal uptake of FCH was seen. F-18-Fluoride PET/CT performed the following day demonstrates multiple abnormal focal bone metastases. Generalized skeletal uptake of FCH results in poor contrast between the metastases compared to noninvolved bone. The metabolic activation of bone marrow by erythropoietin could result in false-negative FCH results for detecting bone metastases.
引用
收藏
页码：200 / 202
页数：3
相关论文
共 13 条
  • [1] Detection of bone metastases in patients with prostate cancer by 18F fluorocholine and 18F fluoride PET-CT:: a comparative study
    Beheshti, Mohsen
    Vali, Reza
    Waldenberger, Peter
    Fitz, Friedrich
    Nader, Michael
    Loidl, Wolfgang
    Broinger, Gabriele
    Stoiber, Franz
    Foglman, Ignac
    Langsteger, Werner
    [J]. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2008, 35 (10) : 1766 - 1774
  • [2] Diffuse bone marrow uptake on whole-body F-18 fluorodeoxyglucose positron emission tomography in a patient taking recombinant erythropoietin
    Blodgett, TM
    Ames, JT
    Torok, FS
    McCook, BM
    Meltzer, CC
    [J]. CLINICAL NUCLEAR MEDICINE, 2004, 29 (03) : 161 - 163
  • [3] [18F]fluorocholine PET/CT imaging for the detection of recurrent prostate cancer at PSA relapse:: experience in 100 consecutive patients
    Cimitan, Marino
    Bortolus, Roberto
    Morassut, Sandro
    Canzonieri, Vincenzo
    Garbeglio, Antonio
    Baresic, Tanja
    Borsatti, Eugenio
    Drigo, Annalisa
    Trovo, Mauro G.
    [J]. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2006, 33 (12) : 1387 - 1398
  • [4] Even-Sapir E, 2006, J NUCL MED, V47, P287
  • [5] Positron emission tomography/computed tomography with F-18-fluorocholine for restaging of prostate cancer patients:: Meaningful at PSA < 5 ng/ml?
    Heinisch, M
    Dirisamer, A
    Loidl, W
    Stoiber, F
    Gruy, B
    Haim, S
    Langsteger, W
    [J]. MOLECULAR IMAGING AND BIOLOGY, 2006, 8 (01) : 43 - 48
  • [6] Evaluation of [18F]-choline PET/CT for staging and restaging of prostate cancer
    Husarik, Daniela B.
    Miralbell, Raymond
    Dubs, Markus
    John, Hubert
    Giger, Olivier T.
    Gelet, Albert
    Cservenyak, Tibor
    Hany, Thomas F.
    [J]. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2008, 35 (02) : 253 - 263
  • [7] Johnston KL, 2005, HAEMATOLOGICA, V90, P88
  • [8] Langsteger W, 2011, Q J NUCL MED MOL IM, V55, P448
  • [9] Role of whole-body 18F-choline PET/CT in disease detection in patients with biochemical relapse after radical treatment for prostate cancer
    Pelosi E.
    Arena V.
    Skanjeti A.
    Pirro V.
    Douroukas A.
    Pupi A.
    Mancini M.
    [J]. La radiologia medica, 2008, 113 (6) : 895 - 904
  • [10] Diffusely increased F-18FDG uptake in bone marrow in a patient with acute anemia and recent erythropoietin therapy
    Plantade, A
    Montravers, F
    Selle, F
    Izrael, V
    Talbot, JN
    [J]. CLINICAL NUCLEAR MEDICINE, 2003, 28 (09) : 771 - 772
12